A study has been launched to investigate the benefits of a new injectable medication for those with knee osteoarthritis.
The condition can have a profound impact on a person’s life, leading to physical limitations, ongoing pain and joint instability.
There are broader implications too which can make it difficult for those with the condition to engage in social, community and occupational activities.
Significant resources and expertise are being directed towards the disease, and a number of clinical trials and research studies are underway to develop new interventions and tests that may alleviate the symptoms of the condition.
One of these promising trials is being led by Professor David Hunter and his team from the Kolling Institute and Royal North Shore Hospital.
The Excellence Study will evaluate a new injectable medication that has been formulated to provide both short-term and long-acting relief from pain, inflammation and mobility impairments.
Many current medications for knee osteoarthritis offer only short-term relief, while this new medication may offer relief for up to six months.
Volunteers are being recruited for the study and further community support is needed.
To find out more about joining the trial, call 9463 1774 or see here.